Rheological properties of erythrocytes in patients with high risk of cardiovascular disease.
Rheological properties of erythrocytes from patients with high risk of cardiovascular disease (CVD) were analyzed in relation to individual patient risk factors as well as to the medication. Additionally, comparative statistical analysis was performed considering plasma concentration of the selected mediators of vascular endothelium: 6-keto-prostaglandin F(1alpha) (PGF(1alpha)), sVCAM-1 and E-selectin adhesion molecules and interleukin-6 (IL-6). It was found that antihypertensive therapy with angiotensin-converting enzyme inhibitor (ACEI) is accompanied by improvement of RBC rheology: the increase of deformability and the decrease of aggregability. This improvement is probably mediated by endothelial prostacyclin and nitric oxide which are generated by ACEI. A correlation was observed between RBC deformability/aggregability and the patient's hematocrit level, what implicates that the hematocrit level should be explicitly taken into consideration when investigating rheological properties of erythrocytes. A strong relationship was also found between the plasma concentration of sVCAM-1 and patient's age.
Fornal
M
M
Department of Internal Medicine and Gerontology, Collegium Medicum, Jagiellonian University, Krakow, Poland. Fornal@su.krakow.pl
Korbut
R A
RA
Lekka
M
M
Pyka-Fościak
G
G
Wizner
B
B
Styczen
J
J
Grodzicki
T
T
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D002318:Cardiovascular Diseases / Q000175:diagnosis* / Q000473:pathology*; D019040:E-Selectin / Q000378:metabolism; D011464:Epoprostenol / Q000494:pharmacology; D004903:Erythrocyte Aggregation; D004907:Erythrocyte Deformability; D004912:Erythrocytes / Q000166:cytology*; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012212:Rheology / Q000379:methods*; D012307:Risk Factors
D000806:Angiotensin-Converting Enzyme Inhibitors; D019040:E-Selectin; D015850:Interleukin-6; D011464:Epoprostenol